FDA Finalizes First Guidance for Psychedelic Clinical Trials

NORTH AMERICA – Yesterday was a major milestone for anyone keeping tabs on psychedelic medicine and drug policy. The FDA officially published its finalized guidance, “Psychedelic Drugs: Considerations for Clinical Investigations,” in the Federal Register.

BEARD BROS PHARMS
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.